Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) CMO David Nicholas Gee sold 4,323 shares of the company's stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $11.36, for a total transaction of $49,109.28. Following the transaction, the chief marketing officer owned 135,281 shares in the company, valued at $1,536,792.16. This represents a 3.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
David Nicholas Gee also recently made the following trade(s):
- On Friday, August 21st, David Nicholas Gee sold 2,198 shares of Cellebrite DI stock. The shares were sold at an average price of $11.24, for a total value of $24,705.52.
- On Wednesday, August 12th, David Nicholas Gee sold 230 shares of Cellebrite DI stock. The shares were sold at an average price of $16.07, for a total value of $3,696.10.
Cellebrite DI Stock Performance
CLBT stock opened at $11.29 on Wednesday. The stock's 50 day simple moving average is $14.21 and its 200 day simple moving average is $13.81. The company has a market cap of $2.82 billion, a P/E ratio of 51.32, a price-to-earnings-growth ratio of 1.59 and a beta of 1.18. Cellebrite DI Ltd. has a fifty-two week low of $9.58 and a fifty-two week high of $19.98.
Key Cellebrite DI News
Here are the key news stories impacting Cellebrite DI this week:
- Positive Sentiment: Analyst sentiment remains broadly constructive: five analysts maintain Buy ratings, and the consensus price target is $16.70. Lake Street, DA Davidson, JPMorgan and Needham all retained positive ratings despite lowering their targets. Analyst ratings and price targets
- Positive Sentiment: Institutional ownership remains substantial at approximately 45.9%, with several funds—including Principal Financial, Renaissance Technologies and Roubaix Capital—reporting increased positions. This may provide some underlying support for the stock. Institutional ownership data
- Neutral Sentiment: The reported short-interest data shows zero shares sold short and a zero-day short-interest ratio. Because the figures imply no measurable short position and include an anomalous percentage change, they offer little useful signal for CLBT’s near-term direction.
- Negative Sentiment: Cellebrite’s chief marketing officer, David Nicholas Gee, sold an additional 4,323 shares worth about $49,100 on August 24, following a sale of 2,198 shares worth approximately $24,700 on August 21. The transactions reduced his holdings by 3.1% and 1.55%, respectively. The latest sale was conducted under a pre-arranged Rule 10b5-1 plan, which reduces—but does not eliminate—the bearish interpretation. CMO insider sale filing
- Negative Sentiment: The chief revenue officer, Marcus Jewell, sold 12,562 shares for approximately $141,200 on August 21. Multiple executive sales in a short period can pressure sentiment, particularly while the stock is well below its 52-week high. CRO insider sale filing
- Negative Sentiment: Kaplan Fox and Block & Leviton announced investigations into potential securities-law violations involving Cellebrite. The announcements do not establish wrongdoing, but they introduce legal and reputational risk and are likely contributing to selling pressure. Kaplan Fox investigation announcement
Institutional Investors Weigh In On Cellebrite DI
Several institutional investors have recently made changes to their positions in CLBT. Towarzystwo Funduszy Inwestycyjnych PZU SA grew its position in shares of Cellebrite DI by 81.0% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company's stock valued at $34,000 after purchasing an additional 850 shares in the last quarter. Advisory Services Network LLC bought a new position in Cellebrite DI in the 3rd quarter worth about $40,000. CWM LLC increased its position in shares of Cellebrite DI by 57.0% during the fourth quarter. CWM LLC now owns 2,449 shares of the company's stock valued at $44,000 after buying an additional 889 shares during the period. Elevation Wealth Partners LLC purchased a new stake in shares of Cellebrite DI in the second quarter worth about $44,000. Finally, Vestcor Inc purchased a new stake in shares of Cellebrite DI in the third quarter worth about $70,000. Hedge funds and other institutional investors own 45.88% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on the company. JPMorgan Chase & Co. lowered their price target on Cellebrite DI from $20.00 to $16.00 and set an "overweight" rating for the company in a research report on Friday, August 14th. DA Davidson reduced their price objective on Cellebrite DI from $22.00 to $15.00 and set a "buy" rating for the company in a report on Friday, August 14th. Needham & Company LLC decreased their target price on Cellebrite DI from $15.00 to $12.50 and set a "buy" rating for the company in a research report on Friday, August 14th. Lake Street Capital lowered their target price on Cellebrite DI from $21.00 to $15.00 and set a "buy" rating on the stock in a research note on Friday, August 14th. Finally, Weiss Ratings downgraded Cellebrite DI from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Thursday, August 13th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $16.70.
View Our Latest Stock Report on CLBT
About Cellebrite DI
(
Get Free Report)
Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.
The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
